ACTPrecis™ G-U

ACTPrecis™ G-U

Precision Medicine To Orchestrate A Treatment Strategy Based On Core Genes

Seizes Opportunities in Late-Stage Treatment

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the US FDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.


Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.


How to Ensure Your Treatment is Aimed at the Bull's Eye

With targeted therapies approved for Cholangiocarcinoma, genomic testing on FGFR2 fusions, BRAF V600E, IDH1 is recommended on NCCN Guideline.

Gastric cancer patients harbour various types of genomic mutations such as ERBB2 amplification. Genomic testing guides the next treatment options.

Around 20% of late stage Bladder cancer patients harbour FGFR gene mutations and the first targetted therapy is FDA approved for patients with this kind of mutation.


Common Problems in Cancer Treatment

∙ Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results.
∙ Complications and metastases make it difficult to determine an appropriate drug.
∙ Ineffective treatment and cancer relapse after targeted therapy.


Diagnostic Solutions for Various Cancers

Through DNA+RNA next-generation sequencing (NGS), ACTPrecisTM G-U targeted genomic profiling decodes 10 cancer genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate. Treatment can also be modified according to the NGS genomic profiling result to overcome drug resistance.


Treatment Advantages from ACTPrecis™ G-U 

✔ More humane process: Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various fusion genes.

✔ More ideal treatment: Nominates proper targeted options.

✔ More intelligent budgeting: Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Type of patients
Cholangiocarcinoma, gastric cancer, bladder cancer

Specimen requirements
Tumor tissue (FFPE)

Turnaround time 
8 working days*

*starting from the date of receipt of approved samples at our CAP-accredited laboratory


More Stories

ACT Genomics provides the best precision medicine service to every patient every day. Providing patients with the ideal testing experience is our goal. Below, you will find stories from real ACT Genomics patients — about their experiences. We hope these will give you more of an idea of what to expect when you have our test for your needs.

Read More